Thalassemia News and Research

Latest Thalassemia News and Research

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

Penn Medicine to establish new center for treatment and research of blood diseases

Penn Medicine to establish new center for treatment and research of blood diseases

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Sickle cell disease trial completes phase 3 patient enrollment

Sickle cell disease trial completes phase 3 patient enrollment

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Haploidentical bone marrow transplants for sickle cell disease: an interview with Dr. Javier Bolaños Meade

Haploidentical bone marrow transplants for sickle cell disease: an interview with Dr. Javier Bolaños Meade

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

bluebird bio completes $60 million Series D financing

bluebird bio completes $60 million Series D financing

Mechanical treatment shows promise in thalassemia

Mechanical treatment shows promise in thalassemia

Treating Sickle Cell Disease with L-Glutamine

Treating Sickle Cell Disease with L-Glutamine

FDA, EMA grant orphan drug designation to bluebird bio's gene therapy product for adrenoleukodystrophy

FDA, EMA grant orphan drug designation to bluebird bio's gene therapy product for adrenoleukodystrophy

Third Rock Ventures announces formation of Global Blood Therapeutics

Third Rock Ventures announces formation of Global Blood Therapeutics

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

New gene transfer technique can treat beta-thalassemia, sickle cell anemia

New gene transfer technique can treat beta-thalassemia, sickle cell anemia